Loading…
← CockpitCompetitor Analysis › DMII Drugs Made In America Acquisition II Corp.Open in the cockpit ↗

Drugs Made In America Acquisition II Corp.DMIICompetitor analysis, valuation and peers

United States · USD·Financials›Financial Conglomerates
Momentum strong 62
Mkt cap
$652M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$1.43M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Close · USD$10.23
1D-0.1%
1W-0.1%
1M+0.5%
3M+1.0%
6M+2.2%
YTD+3.3%
1Yn/a
ATR %0.1%
52w lowhigh1.0% off high

What Drugs Made In America Acquisition II does

Employees: 2

Drugs Made In America Acquisition II at a glance

Size Drugs Made In America Acquisition II (DMII) is a United States Financials company (Financial Conglomerates) with a market value of $652M, the 2503rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.23 on 18 Nov 2026.

Performance Over six months the shares gained 2.2%, against -1.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 19 in its peer set.

Short interest Short interest is 0.1% of the free float (30 Oct 2026).

Relative performance

9810010221 May 202621 Aug 202618 Nov 2026DMII 102Peer median 98
Six months, rebased to 100: Drugs Made In America Acquisition II against the median of its 20 peers (local-currency closes).

Drugs Made In America Acquisition II financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenue$0$0$0
Revenue growth———
Gross profit$0$0$0
EBITDA-$1.37M-$1.30M-$151,720
Net income$17.7M$4.19M-$151,719
Free cash flow-$646,850-$1.02M-$194,300
Capital expenditure$0$0$0
Total debt$450,000$0$250,100

Quarterly statements and history in the cockpit →

Drugs Made In America Acquisition II competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-20%0%+20%SVOL-ABCSFMTAEVACBCSSOIOSEC600784PATRMRAEXAMFICAC88698DMII6-month return →1-month return →
Up and to the right = strong over both horizons. Drugs Made In America Acquisition II is the large dot.

Drugs Made In America Acquisition II competitors and peer comparison

How Drugs Made In America Acquisition II compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Drugs Made In America Acquisition II against its 20 peers (data as of 18 Nov 2026)
MeasureDMIIPeer medianRank in peer set
1-month return+0.5%+0.2%8th highest of 21
6-month return+2.2%-1.3%4th highest of 19
Distance from 52-week high-1.0%-9.5%3rd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Drugs Made In America Acquisition II DMIIUnited States$652M+2%n/an/an/an/an/a
Svolder SVOL-A.STSweden$667M+42%+1,360%90%n/an/an/a
Bain Capital Specialty Finance BCSFUnited States$684M-20%-8%68%n/an/an/a
Metalla Royalty & Streaming MTA.VCanada$616M+2%+56%17%n/an/an/a
EQV Ventures Acquisition Corp. II EVACUnited States$606M+2%n/an/an/an/an/a
Bain Capital GSS Investment BCSSUnited States$604M+2%n/an/an/an/an/a
Cantor Equity Partners IV CEPFUnited States$591M0%n/an/an/an/an/a
OIO OIOUnited States$584M-5%-4%-85%n/an/an/a
Churchill Capital Corp XII CXIIUnited States$577Mn/an/an/an/an/an/a
Senvest Capital SEC.TOCanada$745M+21%-17%453%n/an/an/a
Luyin Investment 600784.SSChina$563M-28%+4%5%n/an/an/a
Patrizia PAT.DEGermany$765M+6%+19%15%n/an/an/a
RMR RMRUnited States$546M-14%-8%10%n/an/an/a
American Exceptionalism Acquisition AEXAUnited States$526M-7%n/an/an/an/an/a
MidCap Financial Investment MFICUnited States$822M-7%-4%19%n/an/an/a
Tangen Industrikapital TANGEN-B.STSweden$508Mn/a+37%8%n/an/an/a
Acceler8 Ventures AC8.LUnited Kingdom$507M-2%n/an/an/an/an/a
New America Acquisition I NWAXUnited States$500M0%n/an/an/an/an/a
Mountain Lake Acquisition Corp. II MLAAUnited States$493M0%n/an/an/an/an/a
Ares Acquisition Corporation III AACUnited States$491M-6%n/an/an/an/an/a
Monex 8698.TJapan$884M-14%+4%14%n/an/an/a

Questions

Which companies are Drugs Made In America Acquisition II's closest peers?
The cockpit's peer set: Svolder (SVOL-A.ST), Bain Capital Specialty Finance (BCSF), Metalla Royalty & Streaming (MTA.V), EQV Ventures Acquisition Corp. II (EVAC), Bain Capital GSS Investment (BCSS), Cantor Equity Partners IV (CEPF), OIO (OIO), Churchill Capital Corp XII (CXII).
How has Drugs Made In America Acquisition II stock performed?
Over six months to 18 Nov 2026 the shares returned +2.2% against -1.3% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.